Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.

Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.

Methods: Patients received T-DM1 (3.

Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting.

In a real-world setting, this study evaluated clinical parameters and outcomes with the administration of eribulin in heavily pre-treated Indian metastatic breast cancer (MBC) patients using electronic medical records. Among 145 patients, 46.2% were oestrogen/progesterone receptor-positive, 15.

Androgen receptor expression in triple negative breast cancer: A report from a tertiary care center.

Context: The role of androgen receptor (AR) as a prognostic marker in triple negative breast cancer (TNBC) has been ambiguous since existing reports illustrate conflicting results.

Aims: To compare clinicopathological features and survival between AR-positive TNBC and QNBC.

Methods And Material: A total of 281 subjects were included and tissue microarrays (TMA) were constructed using tumor tissue cores from their formalin-fixed paraffin-embedded blocks.

Comparison of Recurrence Risk Prediction by the CanAssist Breast Test and the PREDICT Online Tool in Early Breast Cancer Patients.

Introduction Several methods, such as multi-marker (both gene/protein) tests and online/free tools, are available for the prognostication of early breast cancer (EBC) patients. This article compares the risk assessment between the immunohistochemistry-based (IHC) CanAssist Breast (CAB) test and the online/free prognostic tool PREDICT in EBC patients treated at Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) between May 2017 and June 2022. Methodology The current study cohort comprises 130 patients.

Real-World Evidence of the Impact of CanAssist Breast on Physician's Decision About the Use of Adjuvant Chemotherapy in Early Breast Cancer.

Background Clinicians use prognostic biomarker/multi-gene-based tests for predicting recurrence in hormone receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancer (EBC). CanAssist Beast (CAB) uses the expression of five protein biomarkers in combination with tumor-specific parameters such as tumor size, histopathological grade, and lymph node status to predict the risk of distant recurrence within five years of diagnosis for patients with HR+/HER2-, EBC. The current study aimed to evaluate the impact of prognostic tests on adjuvant chemotherapy decisions by assessing the agreement between clinical and CAB risk stratification as low-risk (LR) or high-risk (HR) for distant recurrence.